进展期-话题@MedSci

#进展期#

74篇内容 | 807人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1814060, encodeId=d15d1814060da, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Front Oncol：新辅助化疗(NAC)对比直接手术治疗局部进展期胃癌合并浆膜侵袭(cT4NxM0)患者的疗效, objectType=article, longId=291786, objectId=f8f1291e86ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8f1291e86ad, replyNumber=0, likeNumber=66, createdTime=2022-03-13, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8f1291e86ad, moduleTitle=Front Oncol：新辅助化疗(NAC)对比直接手术治疗局部进展期胃癌合并浆膜侵袭(cT4NxM0)患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8f1291e86ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814059, encodeId=64fd181405942, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, objectType=article, longId=264987, objectId=306f26498e26, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=306f26498e26, replyNumber=0, likeNumber=60, createdTime=2022-10-10, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=306f26498e26, moduleTitle=Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=306f26498e26)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814064, encodeId=325f181406453, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, objectType=article, longId=300702, objectId=67e2300e0251, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67e2300e0251, replyNumber=0, likeNumber=51, createdTime=2022-04-11, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67e2300e0251, moduleTitle=Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67e2300e0251)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814065, encodeId=7cd418140658d, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, objectType=article, longId=300860, objectId=e92c300860d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e92c300860d9, replyNumber=0, likeNumber=59, createdTime=2022-05-19, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e92c300860d9, moduleTitle=J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e92c300860d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814061, encodeId=201f181406193, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究, objectType=article, longId=291845, objectId=199829184512, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=199829184512, replyNumber=0, likeNumber=41, createdTime=2022-01-23, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=199829184512, moduleTitle=BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=199829184512)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814058, encodeId=84171814058e7, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle= 进展期胃癌腹腔镜手术和开腹手术疗效及机体应激免疫反应对比研究, objectType=article, longId=221014, objectId=9e2522101415, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e2522101415, replyNumber=0, likeNumber=50, createdTime=2022-10-08, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e2522101415, moduleTitle= 进展期胃癌腹腔镜手术和开腹手术疗效及机体应激免疫反应对比研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e2522101415)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814052, encodeId=e4be1814052de, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究, objectType=article, longId=213227, objectId=2d7321322eb9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d7321322eb9, replyNumber=0, likeNumber=75, createdTime=2022-01-20, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d7321322eb9, moduleTitle=Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d7321322eb9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814056, encodeId=a19d1814056b1, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, objectType=article, longId=219910, objectId=405021991089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=405021991089, replyNumber=0, likeNumber=52, createdTime=2022-02-07, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=405021991089, moduleTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=405021991089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814063, encodeId=c7f31814063e8, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle= 帕金森病进展期运动症状管理和非运动症状管理, objectType=article, longId=292422, objectId=a5182924224c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5182924224c, replyNumber=0, likeNumber=39, createdTime=2022-10-04, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5182924224c, moduleTitle= 帕金森病进展期运动症状管理和非运动症状管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5182924224c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814062, encodeId=273e181406232, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, objectType=article, longId=291936, objectId=19f829193697, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19f829193697, replyNumber=0, likeNumber=44, createdTime=2022-10-03, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19f829193697, moduleTitle=J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19f829193697)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814053, encodeId=ee71181405396, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=49, createdTime=2022-05-18, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814054, encodeId=bcb4181405493, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Gastric Cancer：纳武单抗在进展期胃癌中的真实临床疗效, objectType=article, longId=216374, objectId=ed3a2163e41a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed3a2163e41a, replyNumber=0, likeNumber=54, createdTime=2022-02-03, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed3a2163e41a, moduleTitle=Gastric Cancer：纳武单抗在进展期胃癌中的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed3a2163e41a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814055, encodeId=ecbe1814055ae, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=61, createdTime=2022-05-23, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814057, encodeId=85b6181405eb5, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, objectType=article, longId=220829, objectId=c5ee220829b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5ee220829b8, replyNumber=0, likeNumber=23, createdTime=2022-07-25, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5ee220829b8, moduleTitle=Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5ee220829b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814051, encodeId=464b181405160, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, objectType=article, longId=206737, objectId=4e1b206e376a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e1b206e376a, replyNumber=0, likeNumber=50, createdTime=2021-10-13, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e1b206e376a, moduleTitle=JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e1b206e376a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814050, encodeId=b0bc18140507a, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=J AM COLL SURGEONS: 多模式治疗可抑制进展期胃癌术后并发症, objectType=article, longId=189198, objectId=e82a189198cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e82a189198cd, replyNumber=0, likeNumber=52, createdTime=2020-12-02, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e82a189198cd, moduleTitle=J AM COLL SURGEONS: 多模式治疗可抑制进展期胃癌术后并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e82a189198cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814049, encodeId=8353181404931, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=【直击ABC5】Eric P. Winer教授专访：新的研究成果改变进展期乳腺癌临床实践, objectType=article, longId=183951, objectId=9614183951e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9614183951e0, replyNumber=0, likeNumber=0, createdTime=2020-07-28, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9614183951e0, moduleTitle=【直击ABC5】Eric P. Winer教授专访：新的研究成果改变进展期乳腺癌临床实践, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9614183951e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814046, encodeId=5614181404653, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=蔡三军教授：进展期直肠癌治疗的临床思考, objectType=article, longId=160376, objectId=4e6f1603e668, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e6f1603e668, replyNumber=0, likeNumber=0, createdTime=2020-01-30, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e6f1603e668, moduleTitle=蔡三军教授：进展期直肠癌治疗的临床思考, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4e6f1603e668)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814048, encodeId=579d1814048d2, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=可切除的进展期结直肠癌围手术期治疗专家共识（2019）, objectType=article, longId=182028, objectId=20f218202803, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20f218202803, replyNumber=0, likeNumber=25, createdTime=2020-01-20, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20f218202803, moduleTitle=可切除的进展期结直肠癌围手术期治疗专家共识（2019）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20f218202803)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1814045, encodeId=2c131814045ea, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, objectTitle=百例挑一 | 三阴性局部进展期乳腺癌新辅助化疗1例, objectType=article, longId=157661, objectId=212a15e66194, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=212a15e66194, replyNumber=0, likeNumber=62, createdTime=2019-06-29, rootId=0, userName=licz0423, userId=5fca128, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=212a15e66194, moduleTitle=百例挑一 | 三阴性局部进展期乳腺癌新辅助化疗1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=212a15e66194)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

进展期

2020-05-29

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Front Oncol：新辅助化疗(NAC)对比直接手术治疗局部进展期胃癌合并浆膜侵袭(cT4NxM0)患者的疗效

2022-03-13

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Front Oncol：立体定向放疗（SBRT）联合免疫治疗（SBRT-IO）对比TACE治疗局部进展期肝细胞癌患者的疗效

2022-10-10

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Oncologist：局部进展期直肠癌(LARC)患者使用完全新辅助治疗(TNT)模式治疗并未能改善预后

2022-04-11

licz0423 (审核中...)

前往app查看评论内容

#进展期#

J Clin Oncol：国内多中心III期研究表明局部进展期直肠癌术前短程放疗+化疗（TNT）是可行的治疗方案

2022-05-19

licz0423 (审核中...)

前往app查看评论内容

#进展期#

BMC Cancer：双药对比三药新辅助治疗局部进展期胃癌(LAGC)的疗效：倾向评分匹配(PSM)研究

2022-01-23

licz0423 (审核中...)

前往app查看评论内容

#进展期#

进展期胃癌腹腔镜手术和开腹手术疗效及机体应激免疫反应对比研究

2022-10-08

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Clin Cancer Res：局部进展期鼻咽癌患者顺铂两种不同给药方式治疗的疗效和安全性评估：随机对照临床研究

2022-01-20

licz0423 (审核中...)

前往app查看评论内容

#进展期#

J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性

2022-02-07

licz0423 (审核中...)

前往app查看评论内容

#进展期#

帕金森病进展期运动症状管理和非运动症状管理

2022-10-04

licz0423 (审核中...)

前往app查看评论内容

#进展期#

J Immunother Cancer：术前SCRT联合CAPOX和卡瑞利珠单抗治疗局部进展期直肠癌(LARC)的有效性和安全性

2022-10-03

licz0423 (审核中...)

前往app查看评论内容

#进展期#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2022-05-18

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Gastric Cancer：纳武单抗在进展期胃癌中的真实临床疗效

2022-02-03

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2022-05-23

licz0423 (审核中...)

前往app查看评论内容

#进展期#

Nat Commun：胃切除术联合术中广泛腹腔灌洗(EIPL)治疗局部进展期胃癌(AGC)患者的3年生存分析： III期临床研究SEIPLUS

2022-07-25

licz0423 (审核中...)

前往app查看评论内容

#进展期#

JCO：帕博利珠单抗一线治疗进展期肾透明细胞癌患者一线治疗的ORR可达36.4％

2021-10-13

licz0423 (审核中...)

前往app查看评论内容

#进展期#

J AM COLL SURGEONS: 多模式治疗可抑制进展期胃癌术后并发症

2020-12-02

licz0423 (审核中...)

前往app查看评论内容

#进展期#

【直击ABC5】Eric P. Winer教授专访：新的研究成果改变进展期乳腺癌临床实践

2020-07-28

licz0423 (审核中...)

前往app查看评论内容

#进展期#

蔡三军教授：进展期直肠癌治疗的临床思考

2020-01-30

licz0423 (审核中...)

前往app查看评论内容

#进展期#

可切除的进展期结直肠癌围手术期治疗专家共识（2019）

2020-01-20

licz0423 (审核中...)

前往app查看评论内容

#进展期#

百例挑一 | 三阴性局部进展期乳腺癌新辅助化疗1例

2019-06-29

科室
- - 订阅+
  - 更多科室
工具
服务